AI Content House
Unleash the Power of Generative AI for Drug Discovery and Launch.
With H1’s generative AI, global life sciences organizations can accelerate clinical research and ultimately pave the way for groundbreaking innovations in the field. Embedded in H1’s flagship products, GenosAI™ can simplify complex queries, access insights from vast amounts of unique data sources, and accelerate time to market.
Introducing H1’s GenosAI™
Users of H1’s clinical trial intelligence platform, Trial Landscape, can now supercharge their trial design, diversity planning, and PI & Site selection with insights from GenosAI™. GenosAI™ is a generative AI tool that uses Natural Language Processing (NLP) technology to analyze and respond to all types of data and intelligence questions. Not only can clinical and feasibility teams quickly unlock the power of H1’s global data platform but they can also break down data silos within their internal ecosystem by overlaying GenosAI™ on internal data sources to create a holistic source of truth for their discovery to launch initiatives.
Here are 3 ways GenosAI™ can help you:
Site Selection & Feasibility
- What sites have run diabetes phase 2 clinical trials in the past 2 years?
- Which of these trials had BRCA 1/2 positive as inclusion criteria?
Competitive Intelligence & Trial Design
- What are all the trials running in breast cancer phase 3?
- What is the breakdown of breast cancer phase 3 trials by country?
- What are the breast cancer phase 3 trials running in Spain currently?
Patient Representation
- Which doctors have been administering next-generation sequencing testing for African American patients?
- Of these doctors, which have been principal investigators of phase 3 trials?
Meet GenosAI™
Speak with our team to explore the many ways GenosAI™ can help you accelerate discovery and launch.
